Free Trial

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.24 +0.01 (+2.17%)
As of 09/12/2025 03:59 PM Eastern

MBX vs. HBP, SCYB, COM, NVH, IGX, MDNA, PDP, COV, SVA, and EMH

Should you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Pediapharm (PDP), Covalon Technologies (COV), Sernova (SVA), and Emerald Health Therapeutics (EMH). These companies are all part of the "biotechnology" industry.

Microbix Biosystems vs. Its Competitors

Microbix Biosystems (TSE:MBX) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Microbix Biosystems has higher revenue and earnings than Helix BioPharma. Microbix Biosystems is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$21.13M1.56C$3.39M-C$0.00-117.50
Helix BioPharmaN/AN/A-C$50.55M-C$1.03-1.48

Microbix Biosystems has a net margin of 13.86% compared to Helix BioPharma's net margin of 0.00%. Helix BioPharma's return on equity of 1,803.57% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems13.86% 12.65% 3.82%
Helix BioPharma N/A 1,803.57%-279.98%

Microbix Biosystems has a beta of 0.060098, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Helix BioPharma has a beta of -0.449843, suggesting that its share price is 145% less volatile than the S&P 500.

0.2% of Microbix Biosystems shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Helix BioPharma had 4 more articles in the media than Microbix Biosystems. MarketBeat recorded 4 mentions for Helix BioPharma and 0 mentions for Microbix Biosystems. Helix BioPharma's average media sentiment score of 0.24 beat Microbix Biosystems' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Microbix Biosystems Neutral
Helix BioPharma Neutral

Summary

Microbix Biosystems beats Helix BioPharma on 8 of the 12 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

MetricMicrobix BiosystemsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$32.96MC$236.97MC$5.87BC$9.40B
Dividend Yield2.30%3.78%5.68%6.51%
P/E Ratio-117.5041.0874.5225.78
Price / Sales1.565,000.68518.919.40
Price / Cash4.1313.1937.5683.29
Price / Book1.14103.7512.165.54
Net IncomeC$3.39M-C$90.99MC$3.28BC$301.20M
7 Day PerformanceN/A2.70%0.78%1.40%
1 Month Performance-16.07%21.05%4.87%7.72%
1 Year Performance-32.86%530.95%60.72%36.76%

Microbix Biosystems Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.24
+2.2%
N/A-31.9%C$32.96MC$21.13M-117.50N/A
HBP
Helix BioPharma
N/AC$1.40
+2.9%
N/A+21.6%C$103.82MN/A-1.369
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%
N/A+0.0%C$102.38MN/A0.00N/AHigh Trading Volume
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/A0.00N/A
NVH
Novoheart
N/AC$0.53
+1.9%
N/A+0.0%C$99.98MC$423.50K-13.95N/A
IGX
IntelGenx Technologies
N/AC$0.58
+1.8%
N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up
MDNA
Medicenna Therapeutics
N/AC$1.04
-1.9%
N/A-48.5%C$86.75MN/A-6.5020
PDP
Pediapharm
N/AC$0.30
+1.7%
N/A+0.0%C$66.36MC$11.16M-4.11N/A
COV
Covalon Technologies
N/AC$2.34
+0.9%
N/A-25.4%C$64.16MC$32.99M26.00N/A
SVA
Sernova
N/AC$0.18
+2.9%
C$2.00
+1,011.1%
-33.3%C$59.13MN/A-2.571,959Gap Up
EMH
Emerald Health Therapeutics
N/AC$0.26
-3.8%
N/A+0.0%C$52.28MC$13.02M-0.37161

Related Companies and Tools


This page (TSE:MBX) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners